Oruka Therapeutics Inc’s recent filing unveils that its 10% Owner JANUS HENDERSON GROUP PLC acquired Company’s shares for reported $17067.0 on Aug 16 ’24. In the deal valued at $2.93 per share,5,818 shares were bought. As a result of this transaction, JANUS HENDERSON GROUP PLC now holds 2,117,213 shares worth roughly $29.68 million.
Then, JANUS HENDERSON GROUP PLC bought 189,856 shares, generating $606,873 in total proceeds. Upon buying the shares at $3.20, the 10% Owner now owns 2,081,168 shares.
Before that, JANUS HENDERSON GROUP PLC bought 30,227 shares. Oruka Therapeutics Inc shares valued at $92,292 were divested by the 10% Owner at a price of $3.05 per share. As a result of the transaction, JANUS HENDERSON GROUP PLC now holds 2,111,395 shares, worth roughly $29.6 million.
Stifel initiated its Oruka Therapeutics Inc [ORKA] rating to a Buy in a research note published on October 11, 2024; the price target was $49. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. Leerink Partners began covering ORKA with “an Outperform” recommendation on September 17, 2024. TD Cowen started covering the stock on September 16, 2024. It rated ORKA as “a Buy”.
Price Performance Review of ORKA
On Monday, Oruka Therapeutics Inc [NASDAQ:ORKA] saw its stock fall -10.78% to $14.02. Over the last five days, the stock has lost -32.60%. Oruka Therapeutics Inc shares have fallen nearly -27.67% since the year began. Nevertheless, the stocks have risen 29.35% over the past one year. While a 52-week high of $33.00 was reached on 01/06/25, a 52-week low of $10.07 was recorded on 01/13/25. SMA at 50 days reached $22.08, while 200 days put it at $32.36.
Levels Of Support And Resistance For ORKA Stock
The 24-hour chart illustrates a support level at 12.95, which if violated will result in even more drops to 11.87. On the upside, there is a resistance level at 15.33. A further resistance level may holdings at 16.63. The Relative Strength Index (RSI) on the 14-day chart is 25.45, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.95, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.94%. Stochastics %K at 11.56% indicates the stock is a buying.
The most recent change occurred on September 13, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
